Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06746831 · ClinicalTrials.gov registry record · Phase 1
Methamphetamine Isomer Pharmacology in Humans
A Phase 1 study, sponsored by University of Wisconsin, Madison.
- Not yet
- Registry status
- Phase 1
- Development phase
- 17
- Enrollment target
NCT06746831: Clinical Trial Phase 1 study, sponsored by University of Wisconsin, Madison.
NCT06746831 is a Phase 1 study that has not yet begun recruiting, run by University of Wisconsin, Madison. The registered enrollment target is 17 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (72% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06746831, a Phase 1 study, has not yet begun recruiting, sponsored by University of Wisconsin, Madison.
- NOT YET RECRUITING
- Registry status
- Phase 1
- Development phase
- 17 participants
- Enrollment target
Study Summary
This study is being done to understand the metabolism and impairment profile of methamphetamine (meth). Meth exists as two chemical structures that are mirror images of each other: R-meth and S-meth. S-meth is a strong central nervous system stimulant and used to treat attention deficit disorder (ADD). R-meth is not a strong central nervous system stimulant and is available over-the-counter in nasal decongestant sprays.17 healthy participants will be enrolled for 3 study visits and on study for up to 12 weeks.
Primary Outcome
The pharmacokinetic analysis relies on observed drug and metabolite concentration measurements over time and across biological matrices (plasma, whole blood, dried capillary spots, oral fluid, urine) included in this study.
Interventions
- DRUG S-(+)-methamphetamine
- DRUG R-(-)-methamphetamine
- DRUG 1:1 racemic mixture of two isomers
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 17 participants |
| Start Date | 2026-07 |
| Est. Completion | 2028-03 |
| Phase | Phase 1 |
What is known before NCT06746831 opens enrollment
NCT06746831 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 17 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (72% lower).
The record links to 0 conditions, and to 3 interventions - of which S-(+)-methamphetamine is the first listed.
NCT06746831 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06746831 about?
NCT06746831 is a clinical study titled "Methamphetamine Isomer Pharmacology in Humans". This study is being done to understand the metabolism and impairment profile of methamphetamine (meth). Meth exists as two chemical structures that are mirror images of each other: R-meth and S-meth. S-meth is a strong central nervous system stimulant and used to treat attention deficit disorder (AD...
What is the current status of trial NCT06746831?
This trial is currently not yet recruiting. It is a Phase 1 study. The enrollment target is 17 participants. The study started on 2026-07. Estimated completion is 2028-03.
What interventions are being tested in trial NCT06746831?
The interventions under investigation include: S-(+)-methamphetamine (DRUG), R-(-)-methamphetamine (DRUG), 1:1 racemic mixture of two isomers (DRUG).
Who is sponsoring clinical trial NCT06746831?
This trial is sponsored by University of Wisconsin, Madison, which has 1,039 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06746831's enrollment target sits among peer trials
17 1785th of 2000 higher than 215 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02090140 · 17 participants · NA
Microfracture Versus Adipose Derived Stem Cells for the Treatment of Articular Cartilage Defects
- NCT03317860 · 17 participants · NA
Improving Measurement and Treatment of Post-stroke Neglect
- NCT04356469 · 17 participants · Phase 2
TCR Alpha Beta T-cell Depleted Haploidentical HCT in the Treatment of Non-Malignant Hematological Disorders in Children
- NCT04414046 · 17 participants · Phase 2
TCR Alpha Beta T-cell Depleted Haploidentical HCT in the Treatment of Primary Immunodeficiency and Inherited Metabolic Disorders in Children
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia